Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shuo Ma

Showing results (221-230 of 253) with videos related to

Pageof 26
Sort By:
Blood Advances|October 23, 2023
Response-adapted, time-limited venetoclax, umbralisib, and ublituximab for relapsed/refractory chronic lymphocytic leukemiaBrian T Hill, Shuo Ma, Clive S Zent, et al.
American Journal of Hematology|January 23, 2023
Orelabrutinib in relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma patients: Multi-center, single-arm, open-label, phase 2 studyWei Xu, Keshu Zhou, Tingyu Wang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 18, 2019
Final Results of a Randomized, Phase III Study of Rituximab With or Without Idelalisib Followed by Open-Label Idelalisib in Patients With Relapsed Chronic Lymphocytic LeukemiaJeff P Sharman, Steven E Coutre, Richard R Furman, et al.
Blood Advances|March 18, 2024
Subsequent malignant neoplasms in patients previously treated with anti-CD19 CAR T-cell therapyMegan Melody, Narendranath Epperla, Geoffrey Shouse, et al.
Bioinformatics (Oxford, England)|April 13, 2023
EBD: an eye biomarker databaseXueli Zhang, Lingcong Kong, Shunming Liu, et al.
Blood Cancer Journal|March 27, 2025
Double hit & double expressor lymphomas: a multicenter analysis of survival outcomes with CD19-directed CAR T-cell therapyReem Karmali, Geoffrey Shouse, Pallawi Torka, et al.
Lancet (London, England)|June 9, 2023
Lisocabtagene maraleucel in chronic lymphocytic leukaemia and small lymphocytic lymphoma (TRANSCEND CLL 004): a multicentre, open-label, single-arm, phase 1-2 studyTanya Siddiqi, David G Maloney, Saad S Kenderian, et al.
Current Medical Research and Opinion|January 30, 2026
Patient-reported outcomes among patients with mantle cell lymphoma or chronic lymphocytic leukemia receiving pirtobrutinib in the BRUIN phase 1/2 study: final analysisCatherine C Coombs, Jennifer A Woyach, Jennifer R Brown, et al.
Haematologica|May 7, 2016
Phase I study of single-agent CC-292, a highly selective Bruton's tyrosine kinase inhibitor, in relapsed/refractory chronic lymphocytic leukemiaJennifer R Brown, Wael A Harb, Brian T Hill, et al.
The Lancet. Oncology|December 14, 2016
Ibrutinib for patients with rituximab-refractory Waldenström's macroglobulinaemia (iNNOVATE): an open-label substudy of an international, multicentre, phase 3 trialMeletios A Dimopoulos, Judith Trotman, Alessandra Tedeschi, et al.
Pageof 26

Showing results (221-230 of 253) with videos related to

Sort By:
Pageof 26
Blood Advances|October 23, 2023
Response-adapted, time-limited venetoclax, umbralisib, and ublituximab for relapsed/refractory chronic lymphocytic leukemiaBrian T Hill, Shuo Ma, Clive S Zent, et al.
American Journal of Hematology|January 23, 2023
Orelabrutinib in relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma patients: Multi-center, single-arm, open-label, phase 2 studyWei Xu, Keshu Zhou, Tingyu Wang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 18, 2019
Final Results of a Randomized, Phase III Study of Rituximab With or Without Idelalisib Followed by Open-Label Idelalisib in Patients With Relapsed Chronic Lymphocytic LeukemiaJeff P Sharman, Steven E Coutre, Richard R Furman, et al.
Blood Advances|March 18, 2024
Subsequent malignant neoplasms in patients previously treated with anti-CD19 CAR T-cell therapyMegan Melody, Narendranath Epperla, Geoffrey Shouse, et al.
Bioinformatics (Oxford, England)|April 13, 2023
EBD: an eye biomarker databaseXueli Zhang, Lingcong Kong, Shunming Liu, et al.
Blood Cancer Journal|March 27, 2025
Double hit & double expressor lymphomas: a multicenter analysis of survival outcomes with CD19-directed CAR T-cell therapyReem Karmali, Geoffrey Shouse, Pallawi Torka, et al.
Lancet (London, England)|June 9, 2023
Lisocabtagene maraleucel in chronic lymphocytic leukaemia and small lymphocytic lymphoma (TRANSCEND CLL 004): a multicentre, open-label, single-arm, phase 1-2 studyTanya Siddiqi, David G Maloney, Saad S Kenderian, et al.
Current Medical Research and Opinion|January 30, 2026
Patient-reported outcomes among patients with mantle cell lymphoma or chronic lymphocytic leukemia receiving pirtobrutinib in the BRUIN phase 1/2 study: final analysisCatherine C Coombs, Jennifer A Woyach, Jennifer R Brown, et al.
Haematologica|May 7, 2016
Phase I study of single-agent CC-292, a highly selective Bruton's tyrosine kinase inhibitor, in relapsed/refractory chronic lymphocytic leukemiaJennifer R Brown, Wael A Harb, Brian T Hill, et al.
The Lancet. Oncology|December 14, 2016
Ibrutinib for patients with rituximab-refractory Waldenström's macroglobulinaemia (iNNOVATE): an open-label substudy of an international, multicentre, phase 3 trialMeletios A Dimopoulos, Judith Trotman, Alessandra Tedeschi, et al.
Pageof 26